![](/images/graphics-bg.png)
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors
Joint Authors
Grandis, Jennifer Rubin
Egloff, Ann Marie
Source
Issue
Vol. 2009, Issue 2009 (31 Dec. 2009), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2009-07-14
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
The epidermal growth factor receptor- (EGFR-) directed antibody, cetuximab, was FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in 2006.
Additional EGFR-targeting agents in clinical development for SCCHN include other EGFR-directed antibodies, tyrosine kinase inhibitors and antisense DNA.
Although the majority of SCCHN overexpress EGFR, SCCHN clinical responses to EGFR-targeting agents have been modest.
Molecular predictors for SCCHN response to EGFR-targeted therapies have not been identified.
However, molecular correlate studies in lung cancer and colon cancer, which have EGFR-targeted therapeutics FDA-approved for treatment, may provide insights.
We describe candidate predictive markers for SCCHN response to EGFR-targeted therapies and their prevalence in SCCHN.
Clinical response will likely be improved by targeted therapy combination treatments.
Src family kinases mediate EGFR-dependent and -independent tumor progression pathways in many cancers including SCCHN.
Several Src-targeting agents are in clinical development for solid malignancies.
Molecular correlate studies for Src-targeting therapies are few and biomarkers correlated with patient response are limited.
Identifying SCCHN patients who will respond to combined EGFR- and Src-targeting will require further characterization of molecular correlates.
We discuss rationale for EGFR and Src co-targeting for SCCHN treatment and describe recent clinical trials implementing combined Src- and EGFR-targeted therapeutics.
American Psychological Association (APA)
Egloff, Ann Marie& Grandis, Jennifer Rubin. 2009. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology،Vol. 2009, no. 2009, pp.1-12.
https://search.emarefa.net/detail/BIM-506274
Modern Language Association (MLA)
Egloff, Ann Marie& Grandis, Jennifer Rubin. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology No. 2009 (2009), pp.1-12.
https://search.emarefa.net/detail/BIM-506274
American Medical Association (AMA)
Egloff, Ann Marie& Grandis, Jennifer Rubin. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology. 2009. Vol. 2009, no. 2009, pp.1-12.
https://search.emarefa.net/detail/BIM-506274
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-506274